Goodwin recently advised Zalicus Inc. in its announced merger with Epirus Biopharmaceuticals, Inc. The combined company will be named Epirus Biopharmaceuticals and will be listed on Nasdaq. The transaction is subject to customary closing conditions and is expected to close in summer 2014. More information about the transaction is available in the companies’ press release.
Zalicus, based in Cambridge, Mass., is a biopharmaceutical company that discovers and develops treatments for patients suffering from pain and inflammation. In addition, the company has multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus is publicly traded on Nasdaq under ticker ZLCS.
Epirus is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. The company, based in Boston, Mass., has specific, targeted approaches for emerging, high growth global and large markets.